Drug Approval | January 21, 2022
Bristol Myers Squibb receives approval for Abecma in Japan
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
The appointment is key for DefiniGEN as they expand the service portfolio to encompass compound screening
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
Quviviq is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain
First of its kind integrated Heart Health Programme on its Health Station ‘hPod’
Unlike most data analysis services, Dolomite Bio will accept sample sizes ranging from as little as one sample, to as many as the research project requires
They will commercialize molnupiravir in the international markets
The company will receive an upfront payment as well as regulatory and sales based milestone payments from Lotus
First launches expected in H1 2022
Ram’s appointment follows the launch of the CDI India division in October 2021.
Subscribe To Our Newsletter & Stay Updated
